44
PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.
 dihydropyrimidine dehydrogenase (DPD) deficiency: Subject; dihydropyrimidine dehydrogenase (DPD) deficiency: Subject.Disorder; lethal adverse reactions: Effect; 5-fluorouracil (5-FU)-based chemotherapy: Treatment; cancer: Treatment.Disorder; 5-fluorouracil: Treatment.Drug; chemotherapy: Treatment.Route
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 dihydropyrimidine dehydrogenase (DPD) deficiency: Subject; dihydropyrimidine dehydrogenase (DPD) deficiency: Subject.Disorder; lethal adverse reactions: Effect; 5-fluorouracil (5-FU)-based chemotherapy: Treatment; cancer: Treatment.Disorder; 5-fluorouracil: Treatment.Drug; chemotherapy: Treatment.Route